| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.042 | 0.8 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.011 | 0.8 |